Clear Regulatory & Go-To-Market Strategy

BiondVax has a unique go-to-market strategy, looking first to obtain regulatory approval for its lead candidate M-001 as a primer to a pandemic or seasonal vaccine. Once sufficient safety and efficacy data has been collected, the product will be further tested, looking for approval as a universal standalone vaccine for any existing or future pandemic or seasonal flu.